$1.08
4.42%
Nasdaq, Sep 02, 10:16 pm CET
ISIN
US87990A1060
Symbol
TNYA

Tenaya Therapeutics Inc Stock price

$1.08
+0.39 55.78% 1M
+0.13 14.06% 6M
-0.35 24.48% YTD
-1.60 59.70% 1Y
-3.48 76.32% 3Y
-14.27 92.96% 5Y
-14.27 92.96% 10Y
-14.27 92.96% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.05 4.42%
ISIN
US87990A1060
Symbol
TNYA
Industry

Key metrics

Basic
Market capitalization
$176.0m
Enterprise Value
$104.3m
Net debt
positive
Cash
$71.7m
Shares outstanding
163.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.8
Financial Health
Equity Ratio
77.4%
Return on Equity
-119.7%
ROCE
-94.1%
ROIC
-218.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-94.1m | $-95.9m
EBIT
$-103.0m | $-104.3m
Net Income
$-99.6m | $-116.0m
Free Cash Flow
$-77.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
20.5% | 10.8%
EBIT
18.9% | 10.1%
Net Income
17.5% | -4.4%
Free Cash Flow
21.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
20.1%
Employees
97
Rev per Employee
$0.0
Show more

Is Tenaya Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Tenaya Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Tenaya Therapeutics Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Tenaya Therapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from Tenaya Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 26 26
23% 23%
-
- Research and Development Expense 77 77
17% 17%
-
-94 -94
21% 21%
-
- Depreciation and Amortization 8.94 8.94
3% 3%
-
EBIT (Operating Income) EBIT -103 -103
19% 19%
-
Net Profit -100 -100
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tenaya Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tenaya Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 18 hours ago
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in a fireside chat at the Morgan Stan...
Neutral
GlobeNewsWire
3 days ago
Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants
Neutral
GlobeNewsWire
26 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual G...
More Tenaya Therapeutics Inc News

Company Profile

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in 2016 and is headquartered in South San Francisco, CA.

Head office United States
CEO Faraz Ali
Employees 97
Founded 2016
Website www.tenayatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today